Download Sample
Add to CartGlobal Drug Eluting Stents Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Type;
Coronary Stenting and Peripheral StentingBy Drug Coating;
Polymer-Based Coatings - [Non - Biodegradable Polymers and Biodegradable Polymers] and Polymer Free Coatings - [Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface]By Scaffold;
Cobalt-Chromium, Platinum-Chromium, Nitinol, and OthersBy Application;
Coronary Artery Disease and Peripheral Artery DiseaseBy End User;
Hospitals and Specialty ClinicsBy Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)Drug Eluting Stents Market Overview
Drug Eluting Stents Market (USD Million)
Drug Eluting Stents Market was valued at USD 7,865.27 million in the year 2024. The size of this market is expected to increase to USD 12,997.98 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.4%.
Global Drug Eluting Stents Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 7.4 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 7.4 % |
| Market Size (2024) | USD 7,865.27 Million |
| Market Size (2031) | USD 12,997.98 Million |
| Market Concentration | Medium |
| Report Pages | 355 |
Major Players
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic
- Biosensors International
- Cook Medical
- Envision Scientific
- Biotronik
- Lepu Medical
- Stentsys
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Drug Eluting Stents Market
Fragmented - Highly competitive market without dominant players
The drug eluting stents market is experiencing robust growth, driven by the rising incidence of cardiovascular diseases. These stents are essential for reducing artery blockages, offering over 60% lower restenosis rates compared to bare-metal stents. As the population ages and cardiovascular risks rise, the demand for these stents is expected to grow, reflecting the broader shift towards advanced interventional cardiology solutions.
Advancements in Stent Technology
Technological innovation is a critical factor shaping this market. New stent designs featuring biodegradable polymers and advanced drug coatings have improved patient outcomes, reducing complications like late stent thrombosis by nearly 30%. These advancements are enhancing safety and long-term efficacy, driving manufacturers to prioritize cutting-edge designs that meet evolving patient needs.
Preference for Minimally Invasive Cardiac Procedures
There is a growing preference for minimally invasive cardiac procedures, a key factor supporting this market's growth. Drug eluting stents are widely chosen for over 70% of percutaneous coronary interventions due to their shorter recovery times and lower complication rates. The increasing adoption of catheter-based interventions further reinforces this trend, as these procedures offer precise, less invasive treatment options.
Growth Outlook for the Market
With continuous technological innovations and a growing patient base, the drug eluting stents market is set for sustained expansion. The increasing emphasis on personalized cardiac care and the rising number of cardiac procedures are expected to drive demand further. Industry analysts anticipate that these stents will remain a cornerstone of interventional cardiology, supporting better long-term patient outcomes.
Drug Eluting Stents Market Recent Developments
-
In 2025, Medtronic plc formed a strategic partnership with a medical device innovator to develop next-generation drug-eluting stents with enhanced biocompatibility.
-
In 2023, Boston Scientific Corporation acquired a biotech firm specializing in innovative drug-eluting stent technologies to broaden its product offerings.
Drug Eluting Stents Market Segment Analysis
In this report, the Drug Eluting Stents Market has been segmented by Type, Drug Coating, Scaffold, Application, End User, and Geography.
Drug Eluting Stents Market, Segmentation by Type
The Drug Eluting Stents Market has been segmented by Type into Coronary Stenting and Peripheral Stenting.
Coronary Stenting
Coronary stenting leads the drug eluting stents market with a dominant 82% share. Its growth is fueled by increasing cases of coronary artery disease, growing preference for minimally invasive cardiac procedures, and ongoing innovation in bioabsorbable and polymer-free stents. The widespread use of drug eluting coronary stents in angioplasty procedures further reinforces their market leadership.
Peripheral Stenting
Peripheral stenting accounts for approximately 18% of the market and is expanding due to the global rise in peripheral artery disease (PAD) and diabetic vascular complications. Technological advancements such as flexible stent designs, drug coatings tailored for peripheral use, and a growing elderly population are key contributors to market growth in this segment.
Drug Eluting Stents Market, Segmentation by Drug Coating
The Drug Eluting Stents Market has been segmented by Drug Coating into Polymer-Based Coatings - Non - Biodegradable Polymers and Biodegradable Polymers, Polymer Free Coatings - Micro Porous Surface, Micro Structured Surface, Slotted Tubular Surface, and Nanoporous Surface.
Polymer-Based Coatings – Non-Biodegradable Polymers
Non-biodegradable polymer coatings hold a 45% market share and are commonly used in traditional drug eluting stents. These coatings enable prolonged drug delivery but are associated with late-stent thrombosis and chronic inflammation, prompting a transition to more advanced alternatives.
Polymer-Based Coatings – Biodegradable Polymers
Biodegradable polymer coatings account for 25% of the market. These stents offer the advantage of controlled drug release followed by natural polymer degradation, reducing long-term risks and improving vascular healing outcomes.
Polymer-Free Coatings – Microporous Surface
Microporous surface stents represent 10% of the market and eliminate the need for polymers by using microscopic surface textures that retain and release drugs. This design improves biocompatibility and reduces the incidence of adverse immune responses.
Polymer-Free Coatings – Microstructured Surface
Microstructured surfaces contribute 8% and feature precise patterns that optimize drug distribution and tissue interaction. These stents are engineered for enhanced re-endothelialization and reduced neointimal hyperplasia.
Polymer-Free Coatings – Slotted Tubular Surface
Slotted tubular surfaces comprise 7% of the market. This stent architecture enhances drug adherence and offers mechanical stability, providing a balance between drug delivery performance and procedural efficiency.
Polymer-Free Coatings – Nanoporous Surface
Nanoporous surfaces account for 5% and are engineered to deliver high-efficiency drug loading with sustained release properties. These stents support long-term efficacy with improved cell compatibility and vascular integration.
Drug Eluting Stents Market, Segmentation by Scaffold
The Drug Eluting Stents Market has been segmented by Scaffold into Cobalt-Chromium, Platinum-Chromium, Nitinol and Others.
Cobalt-Chromium
Cobalt-chromium leads the drug eluting stents market with a commanding 50% share. Its combination of high radial strength, ultra-thin struts, and long-term clinical evidence underpins widespread adoption in percutaneous coronary interventions (PCI) worldwide.
Platinum-Chromium
Platinum-chromium scaffolds capture nearly 25% of total DES demand. Enhanced radiopacity, superior trackability, and flexible architecture make this alloy a top choice for treating complex coronary lesions.
Nitinol
Nitinol devices represent approximately 15% of market volume. Renowned for their shape-memory and super-elastic behavior, nitinol drug eluting stents are gaining traction in peripheral artery disease (PAD) and next-generation self-expanding coronary stents.
Others
The remaining 10% encompasses stainless-steel, magnesium, and bioresorbable scaffolds. These emerging technologies target niche clinical needs such as complete scaffold resorption and improved vessel healing.
Drug Eluting Stents Market, Segmentation by Application
The Drug Eluting Stents Market has been segmented by Application into Coronary Artery Disease and Peripheral Artery Disease.
Coronary Artery Disease (CAD)
Coronary artery disease dominates the drug eluting stents market with an 85% share. Widespread use of angioplasty procedures, increasing prevalence of atherosclerosis, and advancements in coronary stent design continue to fuel demand for DES in CAD management. These stents reduce the risk of restenosis and improve long-term patient outcomes.
Peripheral Artery Disease (PAD)
Peripheral artery disease accounts for 15% of the drug eluting stents market and is steadily expanding. PAD treatment benefits from DES technology, especially in patients with diabetes, chronic limb ischemia, and femoral-popliteal artery blockages. Innovations in flexible, long-length stents and biocompatible coatings are enhancing PAD therapy outcomes.
Drug Eluting Stents Market, Segmentation by End User
The Drug Eluting Stents Market has been segmented by End User into Hospitals and Specialty Clinics.
Hospitals
Hospitals represent a dominant segment in the Drug Eluting Stents Market, owing to their advanced infrastructure and access to skilled interventional cardiologists. Over 70% of procedures involving drug-eluting stents are performed in hospitals due to the availability of catheterization labs and post-operative care facilities. The growing adoption of minimally invasive cardiovascular procedures further drives demand in this segment.
Specialty Clinics
Specialty Clinics are gaining traction in the market due to their focused services and cost-effectiveness. These clinics offer quicker procedures and reduced patient wait times, contributing to approximately 25% of the overall usage of drug-eluting stents. Their rising adoption is also supported by the increasing preference for outpatient settings for routine cardiovascular interventions.
Drug Eluting Stents Market, Segmentation by Geography
In this report, the Drug Eluting Stents Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East & Africa and Latin America.
Regions and Countries Analyzed in this Report
Drug Eluting Stents Market Share (%), by Geographical Region
North America
North America leads the drug eluting stents market with a commanding 37% share. The region benefits from advanced interventional cardiology systems, high healthcare spending, and continuous clinical innovation. The U.S. accounts for the bulk of this demand, supported by a strong presence of leading DES manufacturers.
Europe
Europe holds nearly 29% of the global market, driven by increasing demand for percutaneous coronary interventions (PCI) and a rising elderly population. Countries such as Germany, France, and the UK are leading contributors, supported by widespread access to cardiovascular care.
Asia Pacific
Asia Pacific comprises 23% of the DES market and is experiencing rapid growth. Expanding healthcare infrastructure, growing incidence of coronary artery disease, and supportive government policies in China, India, and Japan are propelling regional demand.
Middle East & Africa
The Middle East & Africa region accounts for about 6% of the DES market. Investment in non-communicable disease prevention, growing urbanization, and public-private initiatives are increasing access to cardiac care services.
Latin America
Latin America contributes approximately 5% of the market. Improved healthcare policies, increased medical tourism, and rising cardiovascular risk factors are boosting demand for drug eluting stents in Brazil, Mexico, and Argentina.
Drug Eluting Stents Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Drug Eluting Stents Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Prevalence of Cardiovascular Diseases
- Technological Advancements in Stent Design
-
Growing Adoption of Minimally Invasive Procedures - The growing acceptance of minimally invasive medical procedures has significantly fueled demand for drug eluting stents. These devices offer dual advantages physical vascular support and controlled drug delivery which greatly reduce the likelihood of restenosis after angioplasty.
Minimally invasive interventions are increasingly favored for their reduced surgical trauma, shorter hospital stays, and quicker recovery periods, particularly in cardiac care. This makes drug eluting stents highly attractive to both patients and physicians looking to enhance outcomes without prolonged downtime.
As hospitals adopt advanced interventional cardiology techniques, drug eluting stents are gaining ground as a standard of care due to their clinical benefits and long-term effectiveness. Their adoption aligns with broader healthcare shifts focused on patient comfort and value-based care.
The continuous push for less invasive, safer treatment alternatives ensures ongoing demand for drug eluting stents, especially as procedural efficiency and success rates continue to improve.
Restraints
- High cost of drug eluting stents
- Stringent regulatory and approval processes
-
Limited availability in low-resource regions - Despite strong clinical value, drug eluting stents remain inaccessible to many patients in low-resource settings due to cost and infrastructure limitations. These stents require skilled handling and advanced procedural support, which are not widely available in underdeveloped healthcare systems.
Public hospitals in emerging economies often operate on restricted budgets, limiting procurement of high-cost medical devices. As a result, patients in rural or economically constrained regions may not benefit from the latest cardiovascular innovations.
Reimbursement issues further compound this challenge. Many healthcare plans in developing countries fail to cover advanced interventions, leaving patients to bear out-of-pocket costs that are often unaffordable.
Until systemic investment in healthcare access and affordability improves, the market penetration of drug eluting stents will remain uneven across global regions.
Opportunities
- Emerging biodegradable stent technologies
- Expansion in emerging healthcare markets
-
Integration with imaging and AI tools - Innovations that combine drug eluting stents with AI and imaging technologies are creating new frontiers in cardiovascular care. These integrations enable enhanced visualization and real-time data analysis, ensuring optimal stent placement and performance.
AI-driven platforms help clinicians interpret imaging data with greater accuracy, reducing human error and improving procedural outcomes. This technology also supports treatment planning and predictive modeling tailored to patient-specific anatomy and risk factors.
Smart imaging systems integrated with stents enable dynamic monitoring of patient progress and early detection of complications, reducing the risk of adverse events and improving long-term outcomes.
As the healthcare sector embraces digital transformation, integrated drug eluting stents are positioned to become a cornerstone of precision interventional cardiology, unlocking opportunities for growth and differentiation in a competitive market.
Drug Eluting Stents Market Competitive Landscape Analysis
Key players in Drug Eluting Stents Market include:
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic
- Biosensors International
- Cook Medical
- Envision Scientific
- Biotronik
- Lepu Medical
- Stentsys
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Drug Coating
- Market Snapshot, By Scaffold
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Drug Eluting Stents Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Prevalence of Cardiovascular Diseases
- Technological Advancements in Stent Design
- Growing Adoption of Minimally Invasive Procedures
- Restraints
- High cost of drug eluting stents
- Stringent regulatory and approval processes
- Limited availability in low-resource regions
- Opportunities
- Emerging biodegradable stent technologies
- Expansion in emerging healthcare markets
- Integration with imaging and AI tools
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Drug Eluting Stents Market, By Type, 2021 - 2031 (USD Million)
- Coronary Stenting
- Peripheral Stenting
- Drug Eluting Stents Market, By Drug Coating, 2021 - 2031 (USD Million)
- Polymer-Based Coatings
- Non - Biodegradable Polymers
- Biodegradable Polymers
- Polymer Free Coatings
- Micro Porous Surface
- Micro Structured Surface
- Slotted Tubular Surface
- Nanoporous Surface
- Polymer-Based Coatings
- Drug Eluting Stents Market, By Scaffold, 2021 - 2031 (USD Million)
- Cobalt-Chromium
- Platinum-Chromium
- Nitinol
- Others
- Drug Eluting Stents Market, By Application, 2021 - 2031 (USD Million)
- Coronary Artery Disease
- Peripheral Artery Disease
- Drug Eluting Stents Market, By End User, 2021 - 2031 (USD Million)
- Hospitals
- Specialty Clinics
- Drug Eluting Stents Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Drug Eluting Stents Market, By Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Abbott Laboratories
- Boston Scientific Corporation
- Terumo Corporation
- Medtronic
- Biosensors International
- Cook Medical
- Envision Scientific
- Biotronik
- Lepu Medical
- Stentsys
- Company Profiles
- Analyst Views
- Future Outlook of the Market